CN106565444A - Extraction method and application of phenanthrene compounds from overground part of Chinese yam - Google Patents
Extraction method and application of phenanthrene compounds from overground part of Chinese yam Download PDFInfo
- Publication number
- CN106565444A CN106565444A CN201610906423.9A CN201610906423A CN106565444A CN 106565444 A CN106565444 A CN 106565444A CN 201610906423 A CN201610906423 A CN 201610906423A CN 106565444 A CN106565444 A CN 106565444A
- Authority
- CN
- China
- Prior art keywords
- compound
- ethanol
- jing
- volume ratio
- yam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 9
- 125000001792 phenanthrenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 title abstract 4
- 235000002722 Dioscorea batatas Nutrition 0.000 title description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 title description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 title description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 title description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000000284 extract Substances 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 238000004440 column chromatography Methods 0.000 claims abstract description 11
- 239000011347 resin Substances 0.000 claims abstract description 10
- 229920005989 resin Polymers 0.000 claims abstract description 10
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000000741 silica gel Substances 0.000 claims abstract 5
- 229910002027 silica gel Inorganic materials 0.000 claims abstract 5
- 239000000499 gel Substances 0.000 claims abstract 2
- 238000010828 elution Methods 0.000 claims description 24
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 16
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002024 ethyl acetate extract Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000003208 petroleum Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 229920005654 Sephadex Polymers 0.000 claims description 7
- 229940125782 compound 2 Drugs 0.000 claims description 7
- 229940126214 compound 3 Drugs 0.000 claims description 7
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 7
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 claims description 7
- 229940125904 compound 1 Drugs 0.000 claims description 6
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- -1 phenanthrene class compound Chemical class 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002481 ethanol extraction Methods 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 229920001503 Glucan Polymers 0.000 claims 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000003810 ethyl acetate extraction Methods 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract description 7
- 229960002632 acarbose Drugs 0.000 abstract description 7
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 238000001179 sorption measurement Methods 0.000 abstract description 7
- 238000005325 percolation Methods 0.000 abstract description 5
- 239000000843 powder Substances 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 244000281702 Dioscorea villosa Species 0.000 description 14
- 235000004879 dioscorea Nutrition 0.000 description 14
- 229940079593 drug Drugs 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 150000002987 phenanthrenes Chemical class 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- BQUYXVYTCAIRQJ-UHFFFAOYSA-N Isobatatasin I Chemical compound OC1=C(OC)C=C2C3=C(OC)C=C(OC)C=C3C=CC2=C1 BQUYXVYTCAIRQJ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- PFKNMJHZSFZCQK-UHFFFAOYSA-N chembl486392 Chemical compound OC1=C(O)C=C2C(C(=O)C=C(C3=O)OC)=C3C=CC2=C1 PFKNMJHZSFZCQK-UHFFFAOYSA-N 0.000 description 3
- LWTLCLCYPAOTPO-UHFFFAOYSA-N dioscoreanone Chemical compound OC1=C(OC)C=C2C(C(=O)C=C(C3=O)OC)=C3C=CC2=C1 LWTLCLCYPAOTPO-UHFFFAOYSA-N 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000011894 semi-preparative HPLC Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- JPKOLMLTXKBHQB-UHFFFAOYSA-N Volucrin Natural products COc1cc(OC)c2c(ccc3c(c(O)c(O)cc23)c4c(O)c(O)cc5c4ccc6cc(OC)cc(OC)c56)c1 JPKOLMLTXKBHQB-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 239000009654 wuzhi Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/34—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/34—Separation; Purification; Stabilisation; Use of additives
- C07C41/36—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/34—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having three rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种山药地上部分菲类化合物的提取方法及应用,属于山药地上部分有效成分的分离及应用技术领域。本发明的技术方案要点为:山药地上部分粗粉用乙醇渗漉提取并浓缩,提取物用有机溶剂萃取,然后经大孔吸附树脂、硅胶、葡聚糖糖凝胶等柱层析分离得到菲类化合物。本发明的山药地上部分提取的四种菲类化合物对a‑葡萄糖苷酶均有显著的抑制活性,在相同条件下均强于降血糖药阿卡波糖的活性。
The invention discloses an extraction method and application of phenanthrene compounds in the aerial part of yam and belongs to the technical field of separation and application of effective components in the aerial part of yam. The key points of the technical scheme of the present invention are: the coarse powder of the aboveground part of yam is extracted and concentrated by ethanol percolation, the extract is extracted with an organic solvent, and then separated by column chromatography such as macroporous adsorption resin, silica gel, dextran sugar gel, etc. to obtain phenanthrene class of compounds. The four phenanthrene compounds extracted from the aerial part of the yam of the present invention all have significant inhibitory activity on a-glucosidase, and are stronger than the activity of the hypoglycemic drug acarbose under the same conditions.
Description
技术领域technical field
本发明属于山药地上部分有效成分的分离及应用技术领域,具体涉及一种山药地上部分菲类化合物的提取方法及应用。The invention belongs to the technical field of separation and application of effective components in aerial parts of yams, and in particular relates to an extraction method and application of phenanthrene compounds in aerial parts of yams.
背景技术Background technique
由于人民生活水平的提高、饮食结构的改变以及少动多坐的生活方式等诸多因素,全球糖尿病发病率增长迅速,糖尿病已经成为继肿瘤、心血管病变之后第三大严重威胁人类健康的慢性疾病。糖尿病的发病过程中最先出现的症状往往是餐后高血糖,即糖尿病的早期征兆,特别是Ⅱ型糖尿病病人,餐后高血糖不仅极易诱发各种并发症,还会极大地提高糖尿病的死亡率。所以,降低餐后血糖是预防糖尿病、减少并发症和降低死亡率的重要措施之一。α-葡萄糖苷酶是碳水化合物消化过程的一种关键酶,它可将多糖或二糖水解成为能够供人体吸收的单糖,因此抑制α-葡萄糖苷酶的活性就能延缓食物中碳水化合物的分解,从而减少葡萄糖的摄入,达到抑制餐后血糖升高的目的。目前临床上的此类药物有阿卡波糖、伏格列波糖和米格列醇。现有的α-葡萄糖苷酶抑制剂种类较少,并伴有肠道副作用,因此人们仍不断致力于开发新型α-葡萄糖苷酶抑制剂。Due to many factors such as the improvement of people's living standards, changes in diet structure, and less active and more sedentary lifestyle, the incidence of diabetes worldwide has increased rapidly. Diabetes has become the third chronic disease that seriously threatens human health after tumors and cardiovascular diseases. . The first symptom in the pathogenesis of diabetes is often postprandial hyperglycemia, which is the early sign of diabetes, especially for patients with type Ⅱ diabetes. Postprandial hyperglycemia not only easily induces various complications, but also greatly increases the risk of diabetes. mortality rate. Therefore, reducing postprandial blood sugar is one of the important measures to prevent diabetes, reduce complications and reduce mortality. α-glucosidase is a key enzyme in the carbohydrate digestion process. It can hydrolyze polysaccharides or disaccharides into monosaccharides that can be absorbed by the human body. Therefore, inhibiting the activity of α-glucosidase can delay the digestion of carbohydrates in food. Decomposition, thereby reducing the intake of glucose, to achieve the purpose of inhibiting postprandial blood sugar rise. Currently clinical drugs of this type include acarbose, voglibose, and miglitol. There are few kinds of α-glucosidase inhibitors available and they are accompanied by intestinal side effects, so people are still working on the development of new α-glucosidase inhibitors.
山药(Disocorea opposita Thunb.)为薯蓣科薯蓣的干燥根茎,具有补脾养肺,固肾益精之功效,临床上广泛用于治疗消渴症、慢性腹泻和虚劳咳嗽等症状,是我国传统的药食同源中药之一,自古以河南焦作(古怀庆府)所产最为地道,故称“怀山药”,为著名的“四大怀药”之一。2006年河南省武陟县获批山药GAP种植基地,解决了野生山药资源短缺,资源可持续利用发展等问题。山药以地下根茎入药,地上部分常作为废弃物被遗弃,导致资源的极大浪费。目前对于山药的研究主要集中于地下根茎(入药部位)的研究,药理研究显示其具有降血糖、降血脂、抗氧化和抗肿瘤等活性。然而对于山药地上部分的研究非常少,未见其在降血糖方面的研究报道。Yam ( Disocorea opposita Thunb.) is the dry rhizome of Dioscorea yam, which has the effects of nourishing the spleen and lungs, strengthening the kidney and benefiting the essence. It is widely used clinically to treat symptoms such as diabetes, chronic diarrhea and consumptive cough. It is one of the traditional Chinese medicines with the same source of medicine and food. Since ancient times, Jiaozuo, Henan (ancient Huaiqing Prefecture) is the most authentic, so it is called "Huaiyam", and it is one of the famous "Four Huaiyao". In 2006, Wuzhi County, Henan Province was approved as a yam GAP planting base, which solved the shortage of wild yam resources and the sustainable utilization and development of resources. Chinese yam uses underground rhizomes as medicine, and the aboveground parts are often discarded as waste, resulting in a great waste of resources. At present, the research on yam mainly focuses on the underground rhizome (medicinal part), pharmacological studies have shown that it has hypoglycemic, hypolipidemic, antioxidative and antitumor activities. However, there are very few studies on the aerial part of yam, and there is no research report on its ability to lower blood sugar.
发明内容Contents of the invention
本发明解决的技术问题是提供了一种山药地上部分菲类化合物的提取方法及应用。The technical problem to be solved by the present invention is to provide an extraction method and application of phenanthrene compounds in the aerial part of yam.
本发明为解决上述技术问题采用如下技术方案,山药地上部分菲类化合物的提取方法,其特征在于具体步骤为:The present invention adopts following technical scheme for solving the above-mentioned technical problem, the extracting method of phenanthrene compound of yam aerial part, is characterized in that concrete steps are:
(1)将阴干的山药地上部分粉碎后,用体积分数为90%-95%的乙醇渗漉提取,合并提取液,减压浓缩得到山药地上部分乙醇提取物,再将该乙醇提取物悬浮于蒸馏水中,依次用石油醚和乙酸乙酯萃取,收集乙酸乙酯萃取液并减压浓缩得到乙酸乙酯萃取物,将乙酸乙酯萃取物经大孔吸附树脂柱层析,依次用体积分数为60%的乙醇、体积分数为80%的乙醇和体积分数为95%的乙醇洗脱,收集体积分数为80%的乙醇洗脱液和体积分数为95%的乙醇洗脱液分别减压浓缩得到80%乙醇洗脱产物和95%乙醇洗脱产物;(1) After crushing the above-ground part of yam dried in the shade, extract by percolation with ethanol with a volume fraction of 90%-95%, combine the extracts, concentrate under reduced pressure to obtain the ethanol extract of the above-ground part of yam, and then suspend the ethanol extract in In distilled water, extract with petroleum ether and ethyl acetate successively, collect the ethyl acetate extract and concentrate under reduced pressure to obtain the ethyl acetate extract, the ethyl acetate extract is subjected to macroporous adsorption resin column chromatography, and the volume fraction is 60% ethanol, ethanol with a volume fraction of 80% and ethanol with a volume fraction of 95% were eluted, and the ethanol eluate with a volume fraction of 80% and the ethanol eluate with a volume fraction of 95% were concentrated under reduced pressure to obtain 80% ethanol elution product and 95% ethanol elution product;
(2)将80%乙醇洗脱产物经常压硅胶柱层析,用石油醚-丙酮溶剂系统在体积比为5:1-1:1的范围内和二氯甲烷-甲醇溶剂系统在体积比为2:1-1:1的范围内梯度洗脱,经TLC鉴定合并相同组分得到初始目标组分,将初始目标组分经常压硅胶柱层析,用二氯甲烷-丙酮溶剂系统在体积比为50:1-10:1的范围内梯度洗脱分别得到化合物1、化合物4和中间目标组分,再将中间目标组分重结晶得到化合物2,其中化合物1的结构式为,化合物2的结构式为,化合物4的结构式为;(2) The product eluted with 80% ethanol is subjected to normal pressure silica gel column chromatography, and the petroleum ether-acetone solvent system is used in the volume ratio of 5:1-1:1 and the methylene chloride-methanol solvent system is used in the volume ratio of Gradient elution within the range of 2:1-1:1, identified by TLC and combined with the same components to obtain the initial target component, the initial target component was subjected to normal pressure silica gel column chromatography, and dichloromethane-acetone solvent system was used in volume ratio Gradient elution in the range of 50:1-10:1 respectively obtains compound 1, compound 4 and intermediate target components, and then recrystallizes the intermediate target components to obtain compound 2, wherein the structural formula of compound 1 is , the structural formula of compound 2 is , the structural formula of compound 4 is ;
(3)将95%乙醇洗脱产物经常压硅胶柱层析,用石油醚-丙酮溶剂系统在体积比为5:1-1:1的范围内和二氯甲烷-甲醇溶剂系统在体积比为2:1-1:1的范围内梯度洗脱,经TLC鉴定合并相同组分得到初始目标组分,将初始目标组分经常压硅胶柱层析,用二氯甲烷-丙酮溶剂系统在体积比为100:0-20:1的范围内梯度洗脱,经TLC鉴定合并相同组分得到中间目标组分,中间目标组分经葡聚糖凝胶柱色谱和半制备HPLC纯化得到化合物3,该化合物3的结构式为,其中葡聚糖凝胶柱色谱的洗脱液为甲醇,半制备HPLC的流动相为体积比75:25的甲醇-水混合溶液。(3) The product eluted with 95% ethanol is subjected to normal pressure silica gel column chromatography, and the petroleum ether-acetone solvent system is used in the volume ratio of 5:1-1:1 and the dichloromethane-methanol solvent system is in the volume ratio of Gradient elution within the range of 2:1-1:1, identified by TLC and combined with the same components to obtain the initial target component, the initial target component was subjected to normal pressure silica gel column chromatography, and dichloromethane-acetone solvent system was used in volume ratio Gradient elution in the range of 100:0-20:1, identified by TLC and combined with the same components to obtain the intermediate target component, the intermediate target component was purified by Sephadex column chromatography and semi-preparative HPLC to obtain compound 3, the The structural formula of compound 3 is , wherein the eluent of Sephadex column chromatography is methanol, and the mobile phase of semi-preparative HPLC is a methanol-water mixed solution with a volume ratio of 75:25.
进一步优选,所述的大孔吸附树脂为Diaion HP-20型大孔吸附树脂,葡聚糖凝胶为Sephadex LH-20型葡聚糖凝胶。Further preferably, the macroporous adsorption resin is Diaion HP-20 type macroporous adsorption resin, and the dextran gel is Sephadex LH-20 type dextran gel.
根据上述方法提取的山药地上部分菲类化合物在制备降血糖药物或保健品中的应用。Application of the phenanthrene compounds from the aerial parts of yam extracted according to the above method in the preparation of hypoglycemic drugs or health care products.
根据上述方法提取的山药地上部分菲类化合物在制备α-葡萄糖苷酶抑制剂类药物或保健品中的应用。Application of the aerial part phenanthrene compounds of Chinese yam extracted according to the above method in the preparation of α-glucosidase inhibitor drugs or health care products.
根据上述方法提取的化合物4在制备α-葡萄糖苷酶抑制剂类药物或保健品中的应用。Application of compound 4 extracted according to the above method in the preparation of α-glucosidase inhibitor drugs or health care products.
本发明通过体外α-葡萄糖苷酶抑制活性研究发现山药地上部分提取的四种菲类化合物对α-葡萄糖苷酶均有显著的抑制作用,其IC50分别为3.04±0.25mM、0.49±0.034mM、4.13±0.023mM和0.07±0.0031mM,明显强于阳性对照药阿卡波糖的活性(IC50为61.57±1.40mM),并且对α-葡萄糖苷酶的抑制率均呈剂量依赖性。In the present invention, through research on the inhibitory activity of α-glucosidase in vitro, it is found that the four phenanthrene compounds extracted from the aerial part of Chinese yam all have significant inhibitory effects on α-glucosidase, and their IC50 are 3.04±0.25mM and 0.49±0.034mM respectively , 4.13±0.023mM and 0.07±0.0031mM, significantly stronger than the activity of the positive control drug acarbose (IC 50 is 61.57±1.40mM), and the inhibition rate of α-glucosidase is dose-dependent.
附图说明Description of drawings
图1是实施例1提取的化合物1对α-葡萄糖苷酶抑制率随药物浓度的变化曲线;Fig. 1 is the variation curve of the compound 1 that embodiment 1 extracts to α-glucosidase inhibitory rate with drug concentration;
图2是实施例2提取的化合物2对α-葡萄糖苷酶抑制率随药物浓度的变化曲线;Fig. 2 is the compound 2 that embodiment 2 extracts to the change curve of α-glucosidase inhibitory rate with drug concentration;
图3是实施例3提取的化合物3对α-葡萄糖苷酶抑制率随药物浓度的变化曲线;Fig. 3 is the variation curve of the compound 3 that embodiment 3 extracts to α-glucosidase inhibitory rate with drug concentration;
图4是实施例1提取的化合物4对α-葡萄糖苷酶抑制率随药物浓度的变化曲线。Fig. 4 is the variation curve of compound 4 extracted in Example 1 on the inhibitory rate of α-glucosidase with drug concentration.
具体实施方式detailed description
以下通过实施例对本发明的上述内容做进一步详细说明,但不应该将此理解为本发明上述主题的范围仅限于以下的实施例,凡基于本发明上述内容实现的技术均属于本发明的范围。The above-mentioned contents of the present invention are described in further detail below through the embodiments, but this should not be interpreted as the scope of the above-mentioned themes of the present invention being limited to the following embodiments, and all technologies realized based on the above-mentioned contents of the present invention all belong to the scope of the present invention.
实施例1Example 1
阴干的山药地上部分8.5kg,粉碎后,用体积分数为95%的乙醇渗漉提取,合并提取液,减压浓缩得总浸膏871.5g,将浸膏悬浮于2倍量水中,依次用5倍量的石油醚和乙酸乙酯萃取,收集乙酸乙酯萃取液并减压浓缩,得到乙酸乙酯萃取物100.2g。将乙酸乙酯萃取物经Diaion HP-20型大孔吸附树脂柱层析,依次用体积分数为60%的乙醇和体积分数为80%的乙醇洗脱,收集体积分数为80%的乙醇洗脱液并减压浓缩,得到80%乙醇洗脱产物45.7g。80%乙醇洗脱产物经常压硅胶柱层析,用石油醚-丙酮(体积比分别为5:1、3:1、2:1和1:1)和二氯甲烷-甲醇(体积比分别为2:1和1:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到10个组分(Fr.1-Fr.10)。Fr.4经常压硅胶柱层析,用二氯甲烷-丙酮(体积比分别为50:1、30:1、20:1和10:1)溶剂系统洗脱,分别得到化合物1(2.6mg)和化合物4(2.1mg)。Shade-dried 8.5kg of aerial part of yam, crushed, extracted by percolation with ethanol with a volume fraction of 95%, combined the extracts, concentrated under reduced pressure to obtain 871.5g of total extract, suspended the extract in 2 times the amount of water, and washed with 5 Double the amount of petroleum ether and ethyl acetate for extraction, the ethyl acetate extract was collected and concentrated under reduced pressure to obtain 100.2 g of ethyl acetate extract. The ethyl acetate extract was subjected to Diaion HP-20 type macroporous adsorption resin column chromatography, eluted with 60% ethanol and 80% ethanol in sequence, and collected 80% ethanol for elution. liquid and concentrated under reduced pressure to obtain 45.7 g of 80% ethanol-eluted product. The product was eluted with 80% ethanol and subjected to normal pressure silica gel column chromatography, using petroleum ether-acetone (volume ratios of 5:1, 3:1, 2:1 and 1:1) and dichloromethane-methanol (volume ratios of 2:1 and 1:1) solvent system elution, identified by TLC and combined the same components to obtain 10 components (Fr.1-Fr.10). Fr.4 Normal pressure silica gel column chromatography, eluting with dichloromethane-acetone (50:1, 30:1, 20:1 and 10:1 by volume) solvent system, respectively, to obtain compound 1 (2.6mg) and compound 4 (2.1 mg).
化合物1和4的波谱数据:7-hydroxy-2,6-dimethoxy-1,4-phenanthrenedione(1):红色无定形粉末,ESI-MS m/z307 [M+Na]+。1H-NMR (400 MHz, DMSO-d 6) δ: 10.35(1H, s, 7-OH), 9.01 (1H, s, H-5), 8.03 (1H, d, J = 8.5 Hz, H-10), 7.87 (1H,d, J = 8.5 Hz, H-9), 7.26 (1H, s, H-8), 6.24 (1H, s, H-3), 3.96 (3H, s, 6-OCH3), 3.86 (3H, s, 2-OCH3); 13C-NMR (400 MHz, DMSO-d 6) δ: 188.6 (C-4), 180.5(C-1), 158.4 (C-2), 152.5 (C-6), 149.6 (C-7), 134.4 (C-8a), 131.7 (C-9),128.7 (C-10a), 124.9 (C-4b), 124.8 (C-4a), 120.0 (C-10), 111.3 (C-3), 110.3(C-8), 106.1 (C-5), 56.4 (2-OCH3), 55.5 (6-OCH3)。Spectral data of compounds 1 and 4: 7-hydroxy-2,6-dimethoxy-1,4-phenanthrenedione (1): red amorphous powder, ESI-MS m/z 307 [M+Na] + . 1 H-NMR (400 MHz, DMSO- d 6 ) δ: 10.35(1H, s, 7-OH), 9.01 (1H, s, H-5), 8.03 (1H, d, J = 8.5 Hz, H- 10), 7.87 (1H,d, J = 8.5 Hz, H-9), 7.26 (1H, s, H-8), 6.24 (1H, s, H-3), 3.96 (3H, s, 6-OCH 3 ), 3.86 (3H, s, 2-OCH 3 ); 13 C-NMR (400 MHz, DMSO- d 6 ) δ: 188.6 (C-4), 180.5(C-1), 158.4 (C-2) , 152.5 (C-6), 149.6 (C-7), 134.4 (C-8a), 131.7 (C-9), 128.7 (C-10a), 124.9 (C-4b), 124.8 (C-4a), 120.0 (C-10), 111.3 (C-3), 110.3 (C-8), 106.1 (C-5), 56.4 (2-OCH 3 ), 55.5 (6-OCH 3 ).
volucrin (4):淡黄色无定形粉末,HRESI-MS m/z 561.1520 [M+Na]+ (calcdfor C32H26O8Na, 561.1525。1H-NMR (400 MHz, acetone-d 6) δ: 9.28 (2H, s, H-5, 5'),7.29 (2H, d, J = 9.1 Hz, H-10, 10'), 6.99 (2H, d, J = 9.1 Hz, H-9, 9'), 6.92(2H, d, J = 2.5 Hz, H-1, 1'), 6.81 (2H, d, J = 2.5 Hz, H-3, 3'), 4.16 (6H, s,4,4¢-OCH3), 3.90 (6H, s, 2,2¢-OCH3)。 Volucrin (4): Pale yellow amorphous powder, HRESI-MS m/z 561.1520 [M+Na] + (calcdfor C 32 H 26 O 8 Na, 561.1525. 1 H-NMR (400 MHz, acetone- d 6 ) δ : 9.28 (2H, s, H-5, 5'),7.29 (2H, d, J = 9.1 Hz, H-10, 10'), 6.99 (2H, d, J = 9.1 Hz, H-9, 9 '), 6.92(2H, d, J = 2.5 Hz, H-1, 1'), 6.81 (2H, d, J = 2.5 Hz, H-3, 3'), 4.16 (6H, s,4,4 ¢-OCH 3 ), 3.90 (6H, s, 2,2¢-OCH 3 ).
实施例2Example 2
阴干的山药地上部分8.5kg,粉碎后,用体积分数为95%的乙醇渗漉提取,合并提取液,减压浓缩得总浸膏871.5g,将浸膏悬浮于2倍量水中,依次用5倍量的石油醚和乙酸乙酯萃取,收集乙酸乙酯萃取液并减压浓缩,得到乙酸乙酯萃取物100.2g。将乙酸乙酯萃取物经Diaion HP-20型大孔吸附树脂柱层析,依次用体积分数为60%的乙醇和体积分数为80%的乙醇洗脱,收集体积分数为80%的乙醇洗脱液并减压浓缩,得到80%乙醇洗脱产物45.7g。80%乙醇洗脱产物经常压硅胶柱层析,用石油醚-丙酮(体积比分别为5:1、3:1、2:1和1:1)和二氯甲烷-甲醇(体积比分别为2:1和1:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到10个组分(Fr.1-Fr.10)。Fr.8重结晶得到化合物2(7.0mg)。Shade-dried 8.5kg of aerial part of yam, crushed, extracted by percolation with ethanol with a volume fraction of 95%, combined the extracts, concentrated under reduced pressure to obtain 871.5g of total extract, suspended the extract in 2 times the amount of water, and washed with 5 Double the amount of petroleum ether and ethyl acetate for extraction, the ethyl acetate extract was collected and concentrated under reduced pressure to obtain 100.2 g of ethyl acetate extract. The ethyl acetate extract was subjected to Diaion HP-20 type macroporous adsorption resin column chromatography, eluted with 60% ethanol and 80% ethanol in sequence, and collected 80% ethanol for elution. liquid and concentrated under reduced pressure to obtain 45.7 g of 80% ethanol-eluted product. The product was eluted with 80% ethanol and subjected to normal pressure silica gel column chromatography, using petroleum ether-acetone (volume ratios of 5:1, 3:1, 2:1 and 1:1) and dichloromethane-methanol (volume ratios of 2:1 and 1:1) solvent system elution, identified by TLC and combined the same components to obtain 10 components (Fr.1-Fr.10). Fr.8 was recrystallized to give Compound 2 (7.0 mg).
化合物2的波谱数据:6,7-dihydroxy-2-methoxy-1,4-phenanthrenedione (2):红色无定形粉末,ESI-MS m/z 293 [M+Na]+。1H-NMR (400 MHz, DMSO-d 6) δ: 8.93 (1H,s, H-5), 7.95 (1H, d, J = 8.4Hz, H-9), 7.78 (1H, d, J = 8.4Hz, H-10), 7.20(1H, s, H-8), 6.21 (1H, s, H-3), 3.84 (3H, s, 2-OCH3)。Spectrum data of compound 2: 6,7-dihydroxy-2-methoxy-1,4-phenanthrenedione (2): red amorphous powder, ESI-MS m/z 293 [M+Na] + . 1 H-NMR (400 MHz, DMSO- d 6 ) δ: 8.93 (1H, s, H-5), 7.95 (1H, d, J = 8.4Hz, H-9), 7.78 (1H, d, J = 8.4Hz, H-10), 7.20(1H, s, H-8), 6.21 (1H, s, H-3), 3.84 (3H, s, 2-OCH 3 ).
实施例3Example 3
阴干的山药地上部分8.5kg,粉碎后,用体积分数为95%的乙醇渗漉提取,合并提取液,减压浓缩得总浸膏871.5g,将浸膏悬浮于2倍量水中,依次用5倍量的石油醚和乙酸乙酯萃取,收集乙酸乙酯萃取液并减压浓缩,得到乙酸乙酯萃取物100.2g。将乙酸乙酯萃取物经Diaion HP-20型大孔吸附树脂柱层析,依次用体积分数为80%的乙醇和体积分数为95%的乙醇洗脱,收集体积分数为95%的乙醇洗脱液并减压浓缩,得到95%乙醇洗脱产物25.0g。95%乙醇洗脱产物经常压硅胶柱层析,用石油醚-丙酮(体积比分别为5:1、3:1、2:1和1:1)和二氯甲烷-甲醇(体积比分别为2:1和1:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到7个组分(Fr.1-Fr.7)。Fr.2经常压硅胶柱层析,用二氯甲烷-丙酮(体积比分别为100:0、50:1和20:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到6个组分 (Fr.2.1-Fr.2.6),Fr.2.6经Sephadex LH-20葡聚糖凝胶柱色谱(甲醇洗脱)和半制备HPLC(流动相:甲醇-水,体积比75:25)纯化得到化合物3(2.4mg)。Shade-dried 8.5kg of aerial part of yam, crushed, extracted by percolation with ethanol with a volume fraction of 95%, combined the extracts, concentrated under reduced pressure to obtain 871.5g of total extract, suspended the extract in 2 times the amount of water, and washed with 5 Double the amount of petroleum ether and ethyl acetate for extraction, the ethyl acetate extract was collected and concentrated under reduced pressure to obtain 100.2 g of ethyl acetate extract. The ethyl acetate extract was subjected to Diaion HP-20 type macroporous adsorption resin column chromatography, eluted with 80% ethanol and 95% ethanol in sequence, and collected 95% ethanol for elution. liquid and concentrated under reduced pressure to obtain 25.0 g of 95% ethanol-eluted product. The product was eluted with 95% ethanol and subjected to normal pressure silica gel column chromatography, using petroleum ether-acetone (volume ratios of 5:1, 3:1, 2:1 and 1:1) and dichloromethane-methanol (volume ratios of 2:1 and 1:1) solvent system elution, identified by TLC and combining the same components to obtain 7 components (Fr.1-Fr.7). Fr.2 Normal pressure silica gel column chromatography, eluted with dichloromethane-acetone (100:0, 50:1 and 20:1 by volume ratio) solvent system, identified by TLC and combined the same components to obtain 6 components (Fr.2.1-Fr.2.6), Fr.2.6 was purified by Sephadex LH-20 Sephadex column chromatography (elution with methanol) and semi-preparative HPLC (mobile phase: methanol-water, volume ratio 75:25) Compound 3 (2.4 mg).
化合物3的波谱数据:7-hydroxy-2,4,6-trimethoxyphenanthrene (3):白色粉末,ESI-MS m/z307 [M+Na]+。1H-NMR (400 MHz, acetone-d 6) δ: 9.04 (1H, s, H-5),7.66 (1H, d, J = 8.8 Hz, H-9), 7.52 (1H, d, J = 8.8 Hz, H-10), 7.37 (1H, s,H-8), 6.98 (1H, d, J = 2.5 Hz, H-1), 6.78 (1H, d, J = 2.5 Hz, H-3), 4.11 (3H,s, 2-OCH3), 3.99 (3H, s, 6-OCH3), 3.92 (3H, s, 4-OCH3); 13C-NMR (100 MHz,acetone-d 6) δ: 160.4 (C-2), 158.7 (C-4), 147.6 (C-6), 147.3 (C-7), 135.9 (C-10a), 128.6 (C-9), 127.7 (C-4b), 126.5 (C-8a), 125.2 (C-10), 116.2 (C-4a),113.5 (C-8), 109.2 (C-5), 102.2 (C-1), 99.7 (C-3), 56.1 (6, 4-OCH3), 55.7 (2-OCH3)。Spectrum data of compound 3: 7-hydroxy-2,4,6-trimethoxyphenanthrene (3): white powder, ESI-MS m/z 307 [M+Na] + . 1 H-NMR (400 MHz, acetone- d 6 ) δ: 9.04 (1H, s, H-5), 7.66 (1H, d, J = 8.8 Hz, H-9), 7.52 (1H, d, J = 8.8 Hz, H-10), 7.37 (1H, s, H-8), 6.98 (1H, d, J = 2.5 Hz, H-1), 6.78 (1H, d, J = 2.5 Hz, H-3) , 4.11 (3H,s, 2-OCH 3 ), 3.99 (3H, s, 6-OCH 3 ), 3.92 (3H, s, 4-OCH 3 ); 13 C-NMR (100 MHz,acetone- d 6 ) δ: 160.4 (C-2), 158.7 (C-4), 147.6 (C-6), 147.3 (C-7), 135.9 (C-10a), 128.6 (C-9), 127.7 (C-4b) , 126.5 (C-8a), 125.2 (C-10), 116.2 (C-4a), 113.5 (C-8), 109.2 (C-5), 102.2 (C-1), 99.7 (C-3), 56.1 (6, 4-OCH 3 ), 55.7 (2-OCH 3 ).
实施例4Example 4
本实施例为上述实施例提取的化合物1-4对α-葡萄糖苷酶的抑制活性测试。This example is a test of the inhibitory activity of compounds 1-4 extracted from the above examples on α-glucosidase.
方法:微孔板法。Method: microplate method.
仪器:酶标仪,恒温培养箱,分析天平,各种型号移液枪。Instruments: microplate reader, constant temperature incubator, analytical balance, various types of pipette guns.
试剂:α-葡萄糖苷酶、4-硝基苯-α-D-吡喃葡萄糖苷、阿卡波糖、磷酸盐缓冲液和二甲基亚砜。Reagents: α-glucosidase, 4-nitrophenyl-α-D-glucopyranoside, acarbose, phosphate buffer, and dimethylsulfoxide.
测试方法:取96孔板,每孔加入2.0mmol/L的PNPG溶液(PBS溶解)80μL,再分别加入10μL不同浓度样品溶液(DMSO溶解),以DMSO为空白对照组,每组设3个平行孔,在酶标仪400nm下测定背景组吸光度(A值)。然后再加入10μL 1.62U/mL α-葡萄糖苷酶溶液(PBS溶解),置于恒温培养箱中,在37℃下恒温孵育30min,测定试验组吸光度(A值)。抑制率(%)用以下公式计算:Test method: Take a 96-well plate, add 80 μL of 2.0 mmol/L PNPG solution (dissolved in PBS) to each well, and then add 10 μL of sample solutions of different concentrations (dissolved in DMSO), use DMSO as the blank control group, and set 3 parallels in each group Wells, the absorbance (A value) of the background group was measured at 400 nm in a microplate reader. Then add 10 μL 1.62U/mL α-glucosidase solution (dissolved in PBS), place in a constant temperature incubator, and incubate at 37°C for 30 minutes, and measure the absorbance (A value) of the test group. Inhibition rate (%) was calculated with the following formula:
抑制率(%)= (ΔA空白-ΔA样品)/ΔA空白×100%Inhibition rate (%) = (ΔA blank - ΔA sample ) / ΔA blank × 100%
ΔA空白为空白组酶与底物反应后A值-背景A值;ΔA blank is the A value after the blank group enzyme reacts with the substrate - the background A value;
ΔA样品为样品组酶与底物反应后A值-背景A值。ΔA sample is the A value after the reaction of the sample group enzyme with the substrate - the background A value.
化合物1-4对α-葡萄糖苷酶的抑制活性结果如下(表1):The results of the inhibitory activity of compounds 1-4 on α-glucosidase are as follows (Table 1):
表1 化合物1-4对α-葡萄糖苷酶的抑制活性Table 1 Inhibitory activity of compounds 1-4 on α-glucosidase
从表1可以看出,实施例1-3提取的化合物1-4对α-葡萄糖苷酶的抑制活性均强于阳性对照药阿卡波糖的活性,其中化合物4的活性最强,远优于阳性对照药阿卡波糖的活性。As can be seen from Table 1, the inhibitory activity of compounds 1-4 extracted in Examples 1-3 to α-glucosidase is stronger than that of the positive control drug acarbose, and the activity of compound 4 is the strongest, far superior to The activity of the positive control drug acarbose.
以上实施例描述了本发明的基本原理、主要特征及优点,本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明原理的范围下,本发明还会有各种变化和改进,这些变化和改进均落入本发明保护的范围内。The above embodiments have described the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited by the above embodiments. What are described in the above embodiments and description are only to illustrate the principles of the present invention. Without departing from the scope of the principle of the present invention, there will be various changes and improvements in the present invention, and these changes and improvements all fall within the protection scope of the present invention.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610906423.9A CN106565444B (en) | 2016-10-18 | 2016-10-18 | The extracting method and application of Chinese yam aerial part phenanthrene class compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610906423.9A CN106565444B (en) | 2016-10-18 | 2016-10-18 | The extracting method and application of Chinese yam aerial part phenanthrene class compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106565444A true CN106565444A (en) | 2017-04-19 |
| CN106565444B CN106565444B (en) | 2019-03-19 |
Family
ID=58533623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610906423.9A Active CN106565444B (en) | 2016-10-18 | 2016-10-18 | The extracting method and application of Chinese yam aerial part phenanthrene class compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106565444B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108440258A (en) * | 2018-04-10 | 2018-08-24 | 南阳师范学院 | The extracting method and its medical application of new luxuriant and rich with fragrance class compound in ground slightly melon |
| CN110742271A (en) * | 2019-10-30 | 2020-02-04 | 广东省农业科学院蚕业与农产品加工研究所 | Application of yam active component as gastrointestinal mucosa injury improver and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104292081A (en) * | 2014-03-07 | 2015-01-21 | 河南大学 | Method for extracting batatasin from plant Chinese yam |
-
2016
- 2016-10-18 CN CN201610906423.9A patent/CN106565444B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104292081A (en) * | 2014-03-07 | 2015-01-21 | 河南大学 | Method for extracting batatasin from plant Chinese yam |
Non-Patent Citations (1)
| Title |
|---|
| LIN ZHANG等: "a-Glucosidase inhibitors from Chinese Yam (Dioscorea opposita Thunb.)", 《FOOD CHEMISTRY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108440258A (en) * | 2018-04-10 | 2018-08-24 | 南阳师范学院 | The extracting method and its medical application of new luxuriant and rich with fragrance class compound in ground slightly melon |
| CN108440258B (en) * | 2018-04-10 | 2019-10-15 | 南阳师范学院 | Extraction method and medical application of phenanthrene compounds in sweet potato |
| CN110742271A (en) * | 2019-10-30 | 2020-02-04 | 广东省农业科学院蚕业与农产品加工研究所 | Application of yam active component as gastrointestinal mucosa injury improver and application thereof |
| CN110742271B (en) * | 2019-10-30 | 2022-06-14 | 广东省农业科学院蚕业与农产品加工研究所 | Use and application of active components of Chinese yam in the preparation of intestinal mucosal injury improving agent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106565444B (en) | 2019-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Juan-Badaturuge et al. | Antioxidant compounds from a South Asian beverage and medicinal plant, Cassia auriculata | |
| CN102153534B (en) | Compound with tyrosinase inhibitory activity as well as preparation method and application thereof | |
| Motta et al. | Galloylquinic acid derivatives from Copaifera langsdorffii leaves display gastroprotective activity | |
| CN102924421B (en) | Preparation method and application of compound having tyrosinase inhibitory activity | |
| CN117736140B (en) | A pyridine alkaloid compound in purslane and its extraction and separation method and use | |
| Wang et al. | New α-glucosidase inhibitors with p-terphenyl skeleton from the mushroom Hydnellum concrescens | |
| CN108774276B (en) | Viburnum sargentii fruit lignan extract and active ingredient and application thereof | |
| CN106727598B (en) | Preparation method of broad-leaved fenghuacao triterpenoids and its application in the preparation of glycosidase inhibitor drugs | |
| CN118164933B (en) | Furan new compound in purslane, and extraction and separation method and application thereof | |
| Wei-Yan et al. | New arbutin derivatives from the leaves of Heliciopsis lobata with cytotoxicity | |
| CN106565444A (en) | Extraction method and application of phenanthrene compounds from overground part of Chinese yam | |
| CN106518629A (en) | Active component of liquorice leaf and structure and application thereof | |
| CN102161649A (en) | Polyphenol type derivatives extracted from mulberry leaves and preparation method and applications thereof | |
| CN109796511B (en) | A kind of new iridoid compound and its preparation method and medical use | |
| CN111548255B (en) | Diterpenoids in Douglas fir and its preparation method and use in pharmacy | |
| CN113004299B (en) | Xanthone compound in mangosteen bark for reducing postprandial blood sugar, and extraction method and application thereof | |
| CN106565811B (en) | The extracting method of the hypoglycemic active ingredient of Chinese yam aerial part and application | |
| CN103239435B (en) | Preparation method of gynura divaricata total caffeoylquinic acid and application in antihyperglycemic agent or health-care product | |
| CN114456191B (en) | Extraction method and application of tocopherol derivatives of overground parts of Chinese yam | |
| CN109897079B (en) | A kind of preparation method and application of coumarin glycoside compound | |
| CN102826982A (en) | Monoterpene compounds prepared from Senecio cannabifolius Less, and extraction method and application thereof | |
| CN103641882B (en) | Novel 2,3-dihydroxyl-30-noroleanolic acid as well as preparation method and application thereof in preparing glycosidase inhibitor medicament | |
| CN103739660B (en) | A kind of compound, its extracting method, its application preparing antitumor drug and antitumor drug of preparation thereof | |
| CN103083342B (en) | Use of flavanoids in the preparation of anti-complement drugs | |
| CN118165054B (en) | Pyran new compound in purslane, and extraction and separation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |